TELOS (TLS) Company Report

Telos Corporation (NASDAQ: TLS) was awarded the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract.
The contract has a ceiling of $151 billion.
This IDIQ contract is designed to enable the rapid delivery of innovative capabilities to the warfighter with increased speed and agility.

Dec 19, 2025, 1:30 PM

Telos Corporation Reports Strong Q3 2025 Results and Provides 2026 Outlook

TLS

Earnings

Guidance Update

Product Launch

Telos Corporation reported strong Q3 2025 financial results, with revenue of $51.4 million, a 116% year-over-year increase, and Adjusted EBITDA of $10.1 million, both exceeding guidance.
The company achieved significant business milestones, including the launch of its new Xacta AI product in early October and securing its first enterprise customer, alongside reaching 504 TSA PreCheck enrollment locations.
For Q4 2025, Telos forecasts revenue between $44 million and $46.3 million and Adjusted EBITDA between $4 million and $5.7 million.
Looking ahead to 2026, existing programs are projected to generate approximately $180 million in revenue with double-digit growth, supplemented by potential additional revenue from Xacta AI sales and new business wins.

Nov 10, 2025, 2:30 PM

Telos Announces First Enterprise-Wide Federal Deployment of Xacta.ai

TLS

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Telos Corporation announced that a U.S. federal agency will be the first to deploy its Xacta.ai™ enterprise-wide, marking a significant advancement for the company's AI-driven governance, risk, and compliance (GRC) platform.
The federal agency, an existing Telos customer, will integrate Xacta.ai across its enterprise environment, leveraging intelligent workflows, real-time insights, and automated compliance mapping.
John B. Wood, Chairman and CEO, stated that this first full enterprise federal deployment represents a major inflection point for Telos, demonstrating the operational capability of their AI vision at mission scale.
In testing, Xacta.ai has shown the ability to shorten compliance tasks from months to days and generate implementation statements in minutes.

Oct 13, 2025, 2:16 PM

TLS Announces Commercial Progress and Supply Chain Expansion

TLS

New Projects/Investments

Revenue Acceleration/Inflection

TLS's Neutron Beam System (NBS) has treated more than 55 patients at Xiamen Humanity Hospital in China, demonstrating over 99% uptime performance, which led to an extended 18-month product warranty.
In July, TLS secured a full-service contract with Neuboron Medical Group, establishing a substantial and recurring revenue stream.
To support scalability, TLS entered an exclusive supply agreement for lithium targets in January 2025 and is developing localized production capabilities in China.
The Boron Neutron Capture Therapy (BNCT) market is projected to grow to over $3 billion globally by 2031, with China and the Asia-Pacific region identified as the fastest-growing opportunity.

Oct 7, 2025, 6:23 PM

Tosi expands global availability of advanced network traffic analysis

TLS

Product Launch

New Projects/Investments

Tosi has announced the global availability of its advanced network traffic analysis, integrated natively into TosiControl, following its initial launch in the US in July.
This functionality provides unified control over OT infrastructure, offering improved threat detection, asset identification, and operational efficiency without requiring new tools or additional complexity.
The advanced network traffic analysis is available as an integrated module within TosiControl for all Tosi customers worldwide and can be activated by existing customers within days without additional hardware.
This expansion addresses a critical market need, as 73% of companies experienced OT attacks in 2024, a significant increase from 49% in 2023.

Oct 7, 2025, 6:00 AM

Telos Launches Xacta.ai to Enhance Cyber Compliance

TLS

Product Launch

New Projects/Investments

Telos Corporation launched Xacta.ai on October 1, 2025, an AI capability integrated into its Xacta cyber governance, risk, and compliance (GRC) platform.
Xacta.ai is designed to dramatically cut compliance timelines and provide expert-level, real-time insights for risk and compliance management.
Pilot testing demonstrated significant efficiency gains, reducing critical compliance tasks from 4-6 months to just nine days and achieving a 93% overall time savings for generating control implementation statements.
The new AI solution is built on 25 years of cyber GRC innovation and expertise, offering capabilities such as Instant Control Implementation, AI-Driven Control Validation, and Risk Remediation.

Oct 1, 2025, 12:37 PM

TAE Life Sciences Reports Positive Preclinical Data for Boron Drugs with Immunotherapy and Extends Kyoto University Partnership

TLS

Product Launch

New Projects/Investments

TAE Life Sciences (TLS) announced preclinical results demonstrating that its novel boronated drugs, when combined with immune checkpoint inhibitors, significantly inhibited tumor growth in preclinical in vivo models, outperforming either immunotherapy alone or Boron Neutron Capture Therapy (BNCT) alone.
These findings are consistent with recent independent 2024 studies, reinforcing the potential for synergistic immune activation and supporting TLS's BNCT-immunotherapy strategy.
Rob Hill, CEO of TLS, stated that these results expand the company's clinical opportunity and strengthen its position in both oncology and the fast-growing immunotherapy markets.
The research partnership with Kyoto University has been extended through December 2026 to ensure continuity in preclinical testing and advance the program towards IND-enabling studies.